Weaver syndrome

Weaver syndrome is an exceptionally rare genetic disorder characterized by accelerated growth that begins prenatally and continues through childhood. This rapid somatic growth is a hallmark, often leading to individuals being significantly taller than their peers. Beyond height, the syndrome presents with a constellation of distinctive features.

Advanced osseous maturation is a consistent finding, meaning bone age is typically advanced compared to chronological age, which can have implications for final adult height. Craniofacial abnormalities are common, often including a prominent forehead, widely spaced eyes (hypertelorism), a broad nasal bridge, and a small chin (micrognathia). Skeletal anomalies can manifest as joint hyperlaxity, contractures, and scoliosis.

Neurological involvement may include developmental delay, intellectual disability, and sometimes seizures. It is crucial to differentiate Weaver syndrome from other overgrowth syndromes, particularly Sotos syndrome, with which it shares some phenotypic overlap but differs in its underlying genetic cause and specific features. The diagnostic process relies on a combination of clinical observation and genetic testing.

The precise genetic etiology of Weaver syndrome was elucidated in 2011, identifying mutations in the EZH2 gene as the primary cause. EZH2 (Enhancer of Zeste Homolog 2) is a key component of the Polycomb Repressive Complex 2 (PRC2), a crucial epigenetic regulator. PRC2 functions by catalyzing the trimethylation of lysine 27 on histone H3 (H3K27me3), a mark associated with gene silencing.

Mutations in EZH2 can lead to either loss-of-function or gain-of-function effects, depending on the specific mutation and its location within the protein. In the context of Weaver syndrome, mutations often result in a gain of function, leading to increased H3K27me3 levels and aberrant gene expression patterns that promote excessive cell proliferation and growth. This understanding of EZH2's role in epigenetic regulation provides a molecular basis for the overgrowth phenotype and opens avenues for potential therapeutic interventions targeting epigenetic pathways.

Weaver syndrome is exceedingly rare, with only a limited number of cases documented in the medical literature. As of December 2013, approximately 48 cases had been confirmed. Its prevalence is estimated to be comparable to that of Sotos syndrome, which is roughly 1 in 15,000 live births.

This extreme rarity poses significant diagnostic challenges. Clinicians must maintain a high index of suspicion to consider Weaver syndrome in individuals presenting with rapid growth and characteristic dysmorphic features. The initial description of the syndrome by Dr.

David Weaver in 1974 laid the groundwork for future recognition, but widespread awareness and genetic testing are essential for accurate diagnosis. The small number of identified cases also limits comprehensive epidemiological studies and the understanding of the full spectrum of clinical variability.

The management of Weaver syndrome is primarily supportive and multidisciplinary, focusing on addressing the specific clinical manifestations. This includes orthopedic interventions for skeletal anomalies, developmental support for cognitive and motor delays, and management of any associated neurological issues. Regular monitoring of growth, bone development, and overall health is paramount.

While the rapid growth is a defining characteristic, the long-term prognosis can vary depending on the severity of associated features, particularly neurological involvement. Advances in genetic sequencing and a deeper understanding of EZH2 function offer hope for more targeted therapies in the future. Research into modulating PRC2 activity or downstream gene expression could potentially offer novel treatment strategies to normalize growth patterns and mitigate developmental challenges for individuals with Weaver syndrome.